ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit April 15, 2021
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update March 30, 2021
ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares March 22, 2021
ContraFect Announces BARDA Contract Award for Up to $86.8 Million and Provides Business Outlook March 11, 2021
ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update November 13, 2020
ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients October 26, 2020
